Hans-Ludwig Schaefer

USPTO Granted Patents = 39 (Patent Applications = 9)

EPO Patents = 20 (Patent Applications = 10)

Average Co-Inventor Count = 6.7

ph-index = 10

Forward Citations = 379(Granted Patents)

Location History:

Hofheim, DE (2002 - 2004)
Hochheim, DE (2002 - 2012)
Frankfurt-am-Main, DE (2009 - 2012)

Company Filing History:

28 out of 1,827

Sanofi-a Ventis Deutschland Gmbh

patents

6 out of 330

Aventis Pharma Deutschland, Gmbh

Years Active: 2002-2012

Loading Chart...

39 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 8173674 - Sulfonyl-phenyl-2H-[1,2,4]oxadiazol-5-one derivatives, processes for their preparation and their use as pharmaceuticals (2012-05-08),

2. 8106023 - 1,4-benzothiepin-1, 1-dioxide derivatives with improved properties method for producing the same, drugs containing said compounds and the use thereof (2012-01-31),

3. 8101583 - 1,4-benzothiepin-1,1-dioxide derivatives which are substituted with fluorine, method for producing the same, drugs containing said compounds and use thereof (2012-01-24),

4. 8048901 - 1,3-substituted cycloalkyl derivatives having acidic, mostly heterocyclic groups, processes for their preparation and their use as pharmaceuticals (2011-11-01),

5. 7956085 - 1,4-benzothiepine 1,1-dioxide derivatives substituted by benzyl radicals, method for their preparation, pharmaceuticals comprising these compounds, and the use thereof (2011-06-07),

6. 7956077 - 2-{-3,'2-(phenyl)-oxazol-4-ylmethoxyl-cyclohexyl methoxy}-propionic acid derivatives used as peroxisome proliferator-activated receptor (PPAR) ligands for the treatment of hyperlipidemia and diabetes (2011-06-07),

7. 7923468 - 1,4-benzothiepin-1,1-dioxide derivatives which are substituted with cyclohexyl groups, method for producing the same, drugs containing said compounds and use thereof (2011-04-12),

8. 7910612 - 4-oxy-N-[1,3,4]-thiadiazol-2-yl-benzene sulfonamides, pharmaceutical compositions and methods for their therapeutic use (2011-03-22),

9. 7872034 - Arylcycloalkyl-substituted alkanoic acid derivatives, processes for their preparation and their use as pharmaceuticals (2011-01-18),

10. 7858647 - N-[1,3,4]-thiadiazol-2-yl-benzene sulfonamides, pharmaceutical compositions thereof and methods for their therapeutic use (2010-12-28),

11. 7772429 - Diphenylazetidinone with improved physiological properties, process for its preparation, medicaments comprising this compound, and its use (2010-08-10),

12. 7732471 - 6-oxazol-4-ylmetholmethoxy-alko-alkoxymethyl substituted benzoic acid derivatives forming peroxisome proliferator—activated receptor (PPAR) ligands, process for their preparation and methods of use thereof (2010-06-08),

13. 7671047 - Cationically substituted diphenylazetidinones, process for their preparation, medicaments comprising these compounds, and their use (2010-03-02),

14. 7615536 - 1,4-benzothiazepine 1,1-dioxide derivative, process for its preparation, medicaments comprising this compound, and use thereof as a hypolipidaemic (2009-11-10),

15. 7601863 - Use of PPAR agonists for the treatment of congestive heart failure (2009-10-13),

Title: Hans-Ludwig Schaefer: Innovations in Pharmacology and Drug Development

Introduction:

Throughout his illustrious career, Hans-Ludwig Schaefer has made significant contributions to the field of pharmacology and drug development. With a total of 39 patents to his name, Schaefer has played a crucial role in advancing medical treatments for various disorders. This article will explore his latest patents, career highlights, collaborations, and the impact of his work on the pharmaceutical industry.

Latest Patents:

One of Schaefer's recent patents is titled "Sulfonyl-phenyl-2H-[1,2,4]oxadiazol-5-one derivatives, processes for their preparation and their use as pharmaceuticals." This invention focuses on compounds with PPARdelta or PPARdelta and PPARgamma agonist activity, which are suitable for treating fatty acid metabolism disorders, glucose utilization disorders, insulin resistance-related disorders, and neurodegenerative disorders of the central and peripheral nervous system.

Another notable patent is titled "1,4-benzothiepin-1, 1-dioxide derivatives with improved properties, method for producing the same, drugs containing said compounds and the use thereof." This patent introduces novel derivatives with improved properties, highlighting their potential application in drug development. These derivatives have the potential to enhance the effectiveness and safety of drugs for various medical conditions.

Career Highlights:

Hans-Ludwig Schaefer's career has been marked by numerous milestones and accolades. Over the years, he has worked with renowned pharmaceutical companies, including Sanofi-Aventis Deutschland GmbH and Aventis Pharma Deutschland GmbH (formerly known as Sanofi-Aventis). His expertise in drug development and pharmacology has led to the successful development and commercialization of several innovative pharmaceutical products.

Collaborations:

Throughout his career, Schaefer has collaborated with esteemed colleagues within the pharmaceutical industry. Notably, he has worked closely with Heiner Glombik and Eugen Falk, both of whom have made substantial contributions to their respective fields. These collaborations have been essential in the advancement of novel drugs and therapeutic approaches.

Conclusion:

Hans-Ludwig Schaefer's career in pharmacology and drug development showcases his dedication to improving medical treatments and patient outcomes. With 39 patents to his name, his innovations in the field have contributed significantly to advancements in pharmacotherapies. Collaborations with colleagues have further amplified the impact of his work. Schaefer's relentless pursuit of novel drug compounds and their successful application in treating various disorders highlight his invaluable contributions to the pharmaceutical industry.

This text is generated by artificial intelligence and may not be accurate.